Recent News

• 06.03.2025 - Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform
• 05.22.2025 - UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
• 05.22.2025 - Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
• 05.14.2025 - Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform
• 05.13.2025 - Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics
• 04.22.2025 - Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs
• 04.09.2025 - Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine
• 04.04.2025 - Renovaro Provides Update to Definitive Agreement with Predictive Oncology
• 03.03.2025 - Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology
• 02.26.2025 - Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine

Recent Filings

• 05.15.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.18.2025 - 8-K Current report
• 04.14.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 04.10.2025 - 8-K Current report
• 03.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.06.2025 - 425 Prospectuses and communications, business combinations
• 03.06.2025 - 8-K Current report
• 02.28.2025 - 8-K Current report
• 02.28.2025 - EX-99.1 EX-99.1